Home ยป COG AALL0331: Lymphoblastic Leukemia

COG AALL0331: Lymphoblastic Leukemia

COG AALL0331: Standard Risk B-Precursor Acute Lymphoblastic Leukemia

Approval Date: 4/11/2005

Principal Investigator: Charles Main, MD

For standard risk acute lymphoblastic leukemia (ALL), to compare the effects of different treatment plans for ALL, to test whether the experimental arms cure more children than standard treatment.

Eligibility:

Each study has its own guidelines for who can participate, called ‘eligibility criteria'. Below is a partial list of criteria for acceptance into the research study. Only the study doctor can make the determination that you meet all eligibility criteria.        

  • Age: > 1 yr and < 10 years old, initial white count < 50,000
  • Previously enrolled on COG AALL03B1
  • Newly diagnosed B-precursor ALL
  • No prior cytotoxic therapy

Contact Person:
Royal Oak
248-551-3230

Status of Clinical Trial:
open and not enrolling